시장보고서

상품코드

1584122

암 지지요법약 시장 : 약물 유형별, 치료 영역별, 유통별, 최종사용자별, 국가별, 지역별-산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Cancer Supportive Care Drugs Market, By Drug Type, By Therapeutic Area, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 301 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

암 지지요법약 시장 규모는 2023년에 214억 1,032만 달러에 달하며, 2024-2032년 CAGR 2.31%로 확대

암 지지요법약 시장 - 시장 역학

암이환율의 상승이 암 지지요법약 시장의 성장을 가속

암 발병률 증가는 암 보조 치료제 시장의 성장을 크게 견인하고 있습니다. 치료 관련 부작용을 관리하기 위해 치료를 찾는 환자가 증가하고 있기 때문입니다. 세계보건기구(WHO)에 따르면 암은 현재 전 세계 사망원인 2위이며, 2020년에는 약 1,000만 명이 암으로 사망할 것으로 예상됩니다. 이러한 우려스러운 추세로 인해 화학요법, 방사선 치료 및 기타 치료를 받는 환자들의 삶의 질을 향상시키기 위한 지지요법에 대한 관심이 높아지고 있습니다. 예를 들어 미국임상종양학회(ASCO)는 암 환자에서 흔히 나타나는 메스꺼움, 통증, 피로 등의 증상 관리의 중요성을 강조하고 있습니다. 또한 국립암연구소(National Cancer Institute)와 같은 기관은 새로운 지지요법약물 연구를 옹호하며 효과적인 치료에 대한 수요를 더욱 증가시키고 있습니다. 의료 서비스 프로바이더가 종합적인 암 치료에 집중함에 따라 지지요법 시장은 이 어려운 건강 상황에서 환자의 결과를 개선해야 하는 중요한 필요성을 반영하여 번창할 것으로 예상됩니다.

암 보조요법제 시장 - 주요 인사이트

당사의 리서치 애널리스트들의 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 2.31%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

약물 유형별로는 구토억제제가 2023년 가장 큰 시장 점유율을 차지할 것으로 전망

치료 영역별로는 화학요법으로 인한 메스꺼움과 구토가 2023년 주요 유형으로 나타났습니다.

유통별로는 병원약국이 2023년 주요 유형으로 꼽혔습니다.

지역별로는 북미가 2023년 매출 1위

암지지요법제 시장 - 세분화 분석 :

암 지지요법 세계 시장은 약물 유형, 치료 영역, 유통, 최종사용자 및 지역에 따라 세분화됩니다.

시장은 약물 유형에 따라 적혈구 조혈 자극제, 과립구 콜로니 자극제(G-CSF), 구토제거제, 비스포스포네이트 등 4가지 범주로 나뉩니다. 구토억제제는 화학요법으로 인한 메스꺼움과 구토를 관리하는 데 필수적인 역할을 하므로 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 적혈구 조혈 자극제 제제는 암 환자의 빈혈을 예방하는 데 도움이 되므로 그 뒤를 잇습니다. 과립구 콜로니 자극인자(G-CSF)도 중요하며 화학요법 후 호중구의 회복을 지원합니다. 비스포스포네이트 계열 약물은 뼈 건강에 중요하지만 다른 약물에 비해 시장 점유율이 상대적으로 낮습니다.

시장은 치료 영역에 따라 화학요법 유발 메스꺼움과 구토, 화학요법 유발 빈혈, 호중구감소증 등 세 가지 범주로 나뉩니다. 화학요법으로 인한 메스꺼움과 구토는 주요 치료 영역이며, 그 주요 이유는 치료 중인 암 환자에서 이러한 부작용의 유병률이 높기 때문입니다. 그 다음으로는 화학요법 유발성 빈혈이 2위를 차지하는데, 이는 많은 환자들이 치료로 인해 적혈구 수가 감소하는 것을 경험하기 때문입니다. 호중구감소증도 중요하지만 다른 치료 영역에 비해 시장 점유율이 작습니다.

암지지요법 의약품 시장 - 지역적 인사이트

암 보조요법제 시장의 지역적 환경은 높은 암 발병률과 첨단화된 의료 인프라가 수요를 견인하는 북미, 특히 미국에서의 괄목할 만한 성장이 특징입니다. 미국암협회에 따르면 미국에서는 2024년 약 190만 명의 암 환자가 새로 발생할 것으로 예상되며, 이에 따라 지지요법약물의 사용이 증가할 것으로 예상됩니다. 유럽 역시 독일, 프랑스 등 여러 국가들이 혁신적인 치료법과 암 치료 개선을 위한 연구 구상에 투자하고 있습니다. 또한 아시아태평양은 중국과 인도와 같은 국가들의 의료비 증가와 암 치료 옵션에 대한 인식이 높아짐에 따라 시장 확대에 있으며, 주목할 만한 지역으로 부상하고 있습니다. 세계보건기구(WHO)는 개발도상국의 암 치료 강화의 필요성을 강조하고 있으며, 이는 지지요법 솔루션의 성장을 더욱 촉진하고 있습니다. 이에 따라 기업은 이러한 다양한 시장별 니즈에 대응하기 위해 지역적 파트너십과 맞춤형 마케팅 전략에 집중하고 있습니다.

암지지요법제 시장 - 경쟁상황:

암 보조요법 시장의 경쟁 환경은 보조요법에 대한 수요 증가에 대응하기 위해 여러 주요 기업이 혁신적인 치료법 개발에 적극 나서고 있는 것이 특징입니다. 암젠, 로슈, 머크 등 주요 기업은 특히 구토억제제 및 과립구 집락자극인자(G-CSF) 분야에서 제품 라인업을 강화하기 위한 연구개발에 집중하고 있습니다. 예를 들어 암젠의 뉴라스타(페그필그라스팀)는 화학요법 환자의 감염 위험 감소에 기여하며 G-CSF 분야의 선두주자로 자리매김하고 있습니다. 또한 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)가 지지요법 연구를 진행하기 위해 다양한 의료 기관과 협력하는 것처럼 공동 연구와 파트너십도 일반적입니다. 또한 화이자(Pfizer)의 Array Biopharma 인수와 같은 최근 인수합병은 지지요법약물을 포함한 암 치료 분야의 기업 포트폴리오를 강화하고 있습니다. 각 기업이 혁신을 지속하고 사업 영역을 확장하는 가운데, 이 시장에서의 경쟁은 여전히 치열하며 암 치료의 환자 결과를 개선하기 위한 진전을 촉진하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 암 지지요법약 업계

경쟁 대시보드
기업 개요
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Johnson &Johnson
- Merck &Co., Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Others

제13장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Cancer Supportive Care Drugs Market size was valued at USD 21,410.32 Million in 2023, expanding at a CAGR of 2.31% from 2024 to 2032.

The Cancer Supportive Care Drugs market encompasses medications designed to alleviate the side effects of cancer treatments, enhance patients' quality of life, and support overall health during therapy. Increasing cancer incidence and the rise in treatment options are fueling the demand for supportive care drugs, with the American Cancer Society reporting that approximately 1.9 million new cancer cases are expected in the U.S. in 2024. Moreover, the growing awareness of the importance of palliative care is encouraging healthcare providers to focus on managing treatment-related adverse effects such as nausea, pain, and fatigue. However, challenges such as high costs associated with novel drugs and reimbursement issues can restrain market growth. On the other hand, opportunities lie in the development of personalized supportive care therapies and expanding markets in developing regions, where rising healthcare expenditure and access to innovative treatments are increasing. Additionally, collaborations between pharmaceutical companies and healthcare institutions to enhance drug efficacy and patient outcomes represent a promising avenue for market expansion.

Cancer Supportive Care Drugs Market- Market Dynamics

Rising Cancer Incidence Accelerates Growth in the Cancer Supportive Care Drugs Market

The rising incidence of cancer is significantly driving growth in the Cancer Supportive Care Drugs market, as more patients seek therapies to manage treatment-related side effects. According to the World Health Organization (WHO), cancer is currently the second leading cause of death globally, with nearly 10 million fatalities in 2020. This alarming trend has prompted an increased focus on supportive care options to enhance the quality of life for patients undergoing chemotherapy, radiation, and other treatments. For instance, the American Society of Clinical Oncology (ASCO) emphasizes the importance of managing symptoms such as nausea, pain, and fatigue, which are prevalent among cancer patients. Additionally, organizations like the National Cancer Institute are advocating for research into novel supportive care drugs, further amplifying the demand for effective treatments. As healthcare providers expand their focus on comprehensive cancer care, the market for supportive therapies is expected to flourish, reflecting a critical need to improve patient outcomes in this challenging health landscape.

Cancer Supportive Care Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.31% over the forecast period (2024-2032)

Based on Drug Type segmentation, Anti-emetics was predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Chemotherapy-Induced Nausea, and Vomiting was the leading type in 2023

Based on distribution segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cancer Supportive Care Drugs Market- Segmentation Analysis:

The Global Cancer Supportive Care Drugs Market is segmented on the basis of Drug Type, Therapeutic Area, Distribution, End-User, and Region.

The market is divided into four categories based on Drug Type: Erythropoiesis-Stimulating Agents, Granulocyte Colony-Stimulating Factors (G-CSFs), Anti-emetics, and Bisphosphonates. Anti-emetics are predicted to show maximum market share due to their essential role in managing chemotherapy-induced nausea and vomiting. Erythropoiesis-stimulating agents follow closely, as they help combat anemia in cancer patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are also significant, supporting neutrophil recovery after chemotherapy. Bisphosphonates, while important for bone health, hold a relatively lower market share compared to the other drug types.

The market is divided into three categories based on Therapeutic Area: Chemotherapy-Induced Nausea and Vomiting, Chemotherapy-Induced Anemia, and Neutropenia. Chemotherapy-induced nausea and Vomiting is the leading therapeutic area, primarily due to the high prevalence of these side effects among cancer patients undergoing treatment. Following this, Chemotherapy-Induced Anemia ranks second, as many patients experience low red blood cell counts due to their therapies. Neutropenia, while also critical, holds a smaller share of the market compared to the other therapeutic areas.

Cancer Supportive Care Drugs Market- Geographical Insights

The geographical landscape of the Cancer Supportive Care Drugs market is characterized by significant growth in North America, particularly in the United States, where a high incidence of cancer and advanced healthcare infrastructure drive demand. According to the American Cancer Society, about 1.9 million new cancer cases were expected in the U.S. in 2024, leading to increased utilization of supportive care drugs. Europe follows closely, with countries like Germany and France investing in innovative treatment options and research initiatives aimed at improving cancer care. Additionally, Asia-Pacific is emerging as a notable region for market expansion, driven by rising healthcare expenditures and increasing awareness of cancer treatment options in countries like China and India. The World Health Organization has emphasized the need for enhanced cancer care in developing regions, further propelling growth in supportive care solutions. As a result, companies are focusing on regional partnerships and tailored marketing strategies to meet the specific needs of these diverse markets.

Cancer Supportive Care Drugs Market- Competitive Landscape:

The competitive landscape of the Cancer Supportive Care Drugs market is marked by the presence of several key players that are actively engaged in developing innovative therapies to meet the growing demand for supportive care. Leading companies such as Amgen, Roche, and Merck are focusing on research and development to enhance their product offerings, particularly in the areas of anti-emetics and granulocyte colony-stimulating factors (G-CSFs). For instance, Amgen's Neulasta (pegfilgrastim) has been a frontrunner in the G-CSF segment, helping to reduce the risk of infection in chemotherapy patients. Collaborations and partnerships are also common, as seen with Bristol-Myers Squibb's alliance with various healthcare institutions to advance research in supportive care. Furthermore, recent acquisitions, such as Pfizer's purchase of Array BioPharma, have strengthened companies' portfolios in cancer therapies, including supportive care drugs. As companies continue to innovate and expand their reach, the competition in this market remains robust, driving advancements that improve patient outcomes in cancer care.

Recent Developments:

In January 2023, Helsinn Healthcare SA and Immedica Pharma AB signed an exclusive long-term agreement to commercialize two cancer-supportive care products, Akynzeo and Aloxi, in key European markets, targeting the prevention of chemotherapy-induced nausea and vomiting.

In August 2024, the FDA approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor, for treating patients with NTRK-positive locally advanced or metastatic solid tumors, enhancing options in cancer supportive care and targeted therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Others

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Erythropoiesis-Stimulating Agents
Granulocyte Colony-Stimulating Factors (G-CSFs)
Anti-emetics
Bisphosphonates

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-Induced Anemia
Neutropenia

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Pediatric Patients
Adult Patients
Geriatric Patients

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Cancer Supportive Care Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Cancer Supportive Care Drugs Market Snippet by Drug Type
- 2.1.2. Cancer Supportive Care Drugs Market Snippet by Therapeutic Area
- 2.1.3. Cancer Supportive Care Drugs Market Snippet by Distribution
- 2.1.4. Cancer Supportive Care Drugs Market Snippet by End-User
- 2.1.5. Cancer Supportive Care Drugs Market Snippet by Country
- 2.1.6. Cancer Supportive Care Drugs Market Snippet by Region
2.2. Competitive Insights

3. Cancer Supportive Care Drugs Key Market Trends

3.1. Cancer Supportive Care Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Cancer Supportive Care Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Cancer Supportive Care Drugs Market Opportunities
3.4. Cancer Supportive Care Drugs Market Future Trends

4. Cancer Supportive Care Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Cancer Supportive Care Drugs Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Cancer Supportive Care Drugs Market Landscape

6.1. Cancer Supportive Care Drugs Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Cancer Supportive Care Drugs Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 7.1.2. Erythropoiesis-Stimulating Agents
- 7.1.3. Granulocyte Colony-Stimulating Factors (G-CSFs)
- 7.1.4. Anti-emetics
- 7.1.5. Bisphosphonates

8. Cancer Supportive Care Drugs Market - By Therapeutic Area

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
- 8.1.2. Chemotherapy-Induced Nausea and Vomiting
- 8.1.3. Chemotherapy-Induced Anemia
- 8.1.4. Neutropenia

9. Cancer Supportive Care Drugs Market - By Distribution

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
- 9.1.2. Hospital Pharmacies
- 9.1.3. Retail Pharmacies
- 9.1.4. Online Pharmacies

10. Cancer Supportive Care Drugs Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Pediatric Patients
- 10.1.3. Adult Patients
- 10.1.4. Geriatric Patients

11. Cancer Supportive Care Drugs Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Cancer Supportive Care Drugs Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Cancer Supportive Care Drugs Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Cancer Supportive Care Drugs Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Cancer Supportive Care Drugs Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Cancer Supportive Care Drugs Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Cancer Supportive Care Drugs Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Amgen Inc.
- 12.2.2. AstraZeneca PLC
- 12.2.3. Bayer AG
- 12.2.4. Bristol-Myers Squibb Company
- 12.2.5. Eisai Co., Ltd.
- 12.2.6. Eli Lilly and Company
- 12.2.7. F. Hoffmann-La Roche AG
- 12.2.8. GlaxoSmithKline plc
- 12.2.9. Johnson & Johnson
- 12.2.10. Merck & Co., Inc.
- 12.2.11. Novartis AG
- 12.2.12. Pfizer Inc.
- 12.2.13. Roche Holding AG
- 12.2.14. Sanofi S.A.
- 12.2.15. Takeda Pharmaceutical Company Limited
- 12.2.16. Teva Pharmaceutical Industries Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us